Mortality in Parkinson’s patients following Covid19 infection in the second wave of the pandemic
Objective: To analyze causes of mortality and death certification in Parkinson’s disease patients who had SARS- CoV2 in Reading, West Berkshire, United Kingdom (UK) Background:…Effects of Subthalamic Nucleus Deep Brain Stimulation on pain in Parkinson disease: Real-life observational prospective study
Objective: To evaluate the effect of subthalamic nucleus deep brain stimulation (STN-DBS) on the different characteristics of pain in patients with Parkinson disease (PD). Background:…A Patient-Centered Outcomes Survey in Parkinson’s Disease: Results of Cognitive Pre-Testing
Objective: To validate the Rush Parkinson's Disease Patient-Centered Outcomes Questionnaire (RUSH-PCO-Q). Background: The RUSH-PCO-Q aims to address the lack of patient-centered outcomes in the field…Predictors of loss to follow-up three years after inclusion in a prospective longitudinal cohort study in people with early Parkinson’s disease
Objective: To investigate potentially modifiable predictors of loss to follow up (LTFU) three years after inclusion in a nationwide mono-centric Parkinson’s cohort study. Background: LTFU…Sex-specific factor analysis-derived profile of neuropsychiatric symptoms predicting dementia conversion in Parkinson’s disease
Objective: Neuropsychiatric symptoms (NPS) are closely associated with cognitive decline in patients with Parkinson’s disease (PD). We investigated which baseline profile of NPS predicts the…Nicotine and influences on hyperkinetic movement disorders
Objective: We describe hyperkinetic movement disorders with a variable response to smoking and nicotine and review clinical and pre-clinical evidence regarding the role of smoking,…Long-term outcome of adaptive DBS using LFP sensing technology
Objective: The aim of this study was to clarify the long-term outcome of Parkinson’s disease patients receiving STN-DBS with adaptive DBS setting. Background: It has…The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD
Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation
Objective: Lu AF82422 is a human IgG1 monoclonal antibody that binds all known forms of alpha-synuclein (aSyn), including monomeric, aggregated and truncated. Data are presented…Evaluation of the association between total electrical energy delivered (TEED) and cognitive function six months after DBS in patients with Parkinson’s disease
Objective: We aimed to investigate the neuropsychological outcome six months after bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkison's disease (PD) patients and…
- « Previous Page
- 1
- …
- 248
- 249
- 250
- 251
- 252
- …
- 338
- Next Page »